PRAME peptide-MHC class I complex

The PRAME peptide-MHC complex is formed when intracellular PRAME protein is processed, and peptide fragments—most notably the ALY (amino acids 300-309) peptide—are presented on the extracellular face of tumor cells by MHC class I molecules, specifically HLA-A*0201[5][6]. These complexes represent canonical tumor-associated antigens, serving as pivotal targets for immunotherapies such as TCR mimic antibodies and engineered T cells. The specific recognition of PRAME peptide-MHC complexes enables immunotherapeutic discrimination of cancer cells from normal tissue, although therapeutic strategies must contend with safety issues related to limited PRAME expression in some non-malignant tissues and the restriction of therapy to patients with the appropriate HLA types[6][10]. Approaches to enhance PRAME antigen presentation, such as epigenetic modulation, are under investigation to improve clinical responses[2].

Other names

PRAME/HLA-A2 complexPRAME peptide/HLA-A*0201 complexPRAME peptide-MHC complexPRAME pMHC

TCR mimic antibodies: Bind specifically to PRAME peptide-MHC complexes and mediate cytotoxicity against cancer cells expressing PRAME. Adoptive T cell therapies: Engineered T cells recognize the complex and kill tumor cells. Epigenetic modulators: EZH2 inhibition enhances PRAME peptide presentation, boosting immune recognition and therapeutic efficacy.